230 related articles for article (PubMed ID: 34119585)
1. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters.
Tan H; Cheung P; Louie AV; Myrehaug S; Niglas M; Atenafu EG; Chu W; Chung HT; Poon I; Sahgal A; Soliman H
Radiother Oncol; 2021 Aug; 161():159-165. PubMed ID: 34119585
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter.
Thompson R; Cheung P; Chu W; Myrehaug S; Poon I; Sahgal A; Soliman H; Tseng CL; Wong S; Ung Y; Beatriz Kinupe Abrahão A; Erler D; Zhang L; Ko YJ; Chung HT
Radiother Oncol; 2020 Jan; 142():236-245. PubMed ID: 31543287
[TBL] [Abstract][Full Text] [Related]
3. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy for distant metastases to the head and neck.
Mutsaers A; Abugharib A; Poon I; Loblaw J; Bayley A; Zhang L; Chin L; Galapin M; Erler D; Sahgal A; Higgins K; Enepekides D; Eskander A; Karam I
Support Care Cancer; 2024 Mar; 32(4):230. PubMed ID: 38488881
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors.
Ji X; Zhao Y; Zhu X; Shen Z; Li A; Chen C; Chu X
Front Oncol; 2020; 10():595781. PubMed ID: 33585211
[TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Nicosia L; Ricchetti F; Rigo M; Attinà G; Vitale C; Pastorello E; Ruggieri R; Alongi F
Strahlenther Onkol; 2022 Oct; 198(10):934-939. PubMed ID: 35499694
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer.
Li S; Dong D; Geng J; Zhu X; Shi C; Zhang Y; Wang H; Zhou S; Wu H; Cai Y; Li Y; Wang W
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e64-e72. PubMed ID: 33629479
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
11. Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression.
Pembroke CA; Fortin B; Kopek N
Radiother Oncol; 2018 Jun; 127(3):493-500. PubMed ID: 29735409
[TBL] [Abstract][Full Text] [Related]
12. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
13. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer.
Li S; Dong D; Geng J; Zhu X; Shi C; Zhang Y; Wang H; Zhou S; Wu H; Cai Y; Li Y; Wang W
Front Oncol; 2019; 9():1080. PubMed ID: 31681609
[No Abstract] [Full Text] [Related]
15. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
16. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
Nagpal SK; Khabra K; Ross G; Kirby AM
Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
[TBL] [Abstract][Full Text] [Related]
17. Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China.
Xu C; Zhao X; Ju X; Shen Y; Qu M; Ye Y; Wang X; Yu C; Gao X; Zhang H
Front Oncol; 2022; 12():879310. PubMed ID: 35574331
[TBL] [Abstract][Full Text] [Related]
18. Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
Franzese C; Comito T; Franceschini D; Loi M; Clerici E; Navarria P; De Rose F; Di Brina L; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2020 May; 146(5):1227-1234. PubMed ID: 32056005
[TBL] [Abstract][Full Text] [Related]
19. Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer.
Wijetunga NA; Dos Anjos CH; Zhi WI; Robson M; Tsai CJ; Yamada Y; Dover L; Gillespie EF; Xu AJ; Yang JT
Cancer Med; 2021 Aug; 10(15):5163-5174. PubMed ID: 34159748
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
Ingrosso G; Detti B; Fodor A; Caini S; Borghesi S; Triggiani L; Trippa F; Russo D; Bruni A; Francolini G; Lancia A; Marinelli L; Di Muzio N; Livi L; Magrini SM; Maranzano E; Musio D; Aristei C; Valeriani M
Clin Transl Oncol; 2021 Aug; 23(8):1577-1584. PubMed ID: 33495981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
